Welcome to hospitalpharma.com
Post Your Own Content
Latest News
Ferumoxytol Approved to Treat Iron Deficiency Anemia in Chronic Kidney DiseaseMedscape
02 Jul 09, 21:22
Do statins cut heart attack risk for the healthy?
Nursing Times
02 Jul 09, 20:50
New Direction at the American Society for Aesthetic Plastic Surgery (ASAPS): An Expert Interview With President Renato Saltz, MD
Medscape
02 Jul 09, 18:45
Patient survey losses will cost GPs £35m
Pulse
02 Jul 09, 17:03
BMA members make stand against assisted suicide
Pulse
02 Jul 09, 17:02
Latest Press Releases
- SCHERING-PLOUGH ANNOUNCES PHASE II AND III DATA FOR CORIFOLLITROPIN ALFA
02 Jul 09
Fleishman-Hillard - Novartis receives Complete Response letter from the US Food and Drug Administration for its investigational vaccine Menveo®
02 Jul 09
PharmiWeb.com - Graceway Pharmaceuticals Acquires Early-stage Dermatological Molecules from Pfizer
02 Jul 09
PharmiWeb.com - Roche launches novel program to ease Tamiflu access to developing economies
02 Jul 09
PharmiWeb - SCHERING-PLOUGH ANNOUNCES PHASE II AND III DATA FOR CORIFOLLITROPIN ALFA
01 Jul 09
Pharmiweb.com
Latest Events
- Pharma CI Conference
15 Sep 09 - 16 Sep 09 - Supporting pharmacists in delivering enhanced services
28 Sep 09 - 28 Sep 09 - TLRs, NLRs and RLRs, pathogens sensors of innate immunity
09 Oct 09 - 09 Oct 09
HospitalPharma.com today | 03 July 2009
Sanofi-aventis's New R&D Model
Sanofi-aventis has presented a new R&D Model Project aimed to boost innovation is the first pillar of the Group’s new strategy which was presented in February 2009 by Christopher A. Viehbacher, Chief Executive Officer of sanofi-aventis.
“The objective of this new R&D model is to propose innovative solutions that respond to specific, unmet needs of patients and continue our success in a very competitive international environment,” declared Christopher A. Viehbacher, Chief Executive Officer of sanofi-aventis. “It is centered on the real needs of patients, the development of scientific networks and openness toward outside entities to strengthen creativity, and a flexible and entrepreneurial approach to research.”
The company claimed "The rapid evolution of the scientific environment, which is bringing about a veritable revolution in biopharmaceutical research, namely in biology, has generated a profound and continuous change in the pharmaceutical environment. To anticipate the consequences of this mutation and to maintain its innovative capacities, sanofi-aventis intends to set in place the most effective R&D organization in the pharmaceutical industry by 2013."
Breaking Drug Discovery Articles
Click the 'more' link below to be taken to the latest journal article entries in the area of drug discovery, provided by http://www.leaddiscovery.co.uk.
Latest Features
World Vaccine Congress Asia: vast regional diversity requires flexibility and targeted portfolios
01 Jul 09
Spanning one third of the globe's circumference and home to more than half of the world's population, the Asia Pacific region is incredibly diverse.
The 10th Annual Congress of the European League Against Rheumatism (EULAR)
18 Jun 09
Field reporter Rhonda Siddall reports from EULAR
Pharmaceutical Curriculum Vitae, Works of Art or Dissertations?
15 Jun 09
Unless it paints the right picture you’re letting the side down!
In a depressed job market, an employer is likely to receive 50+ CVs per job advertised from 5 or more Preferred Agencies and many...
Latest Poll
